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Abstract 
Abstract 
This "Deep Insight" is a detailed subchapter of a general review article and summary on Internet databases for 
cytogeneticists: Internet databases and resources for cytogenetics and cytogenomics. 
I- Bibliography 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) 
PubMed is a widely used and free search engine 
and database of biomedical citations and abstracts, 
based essentially on the MEDLINE database of 
references and abstracts on life sciences and 
biomedical topics. The database is maintained by 
the National Center for Biotechnology Information 
(NCBI), at the U.S. National Library of Medicine 
(NLM), located at the National Institutes of Health 
(NIH), as part of the Entrez system of information 
retrieval. From 1971 to 1997, the online version of 
MEDLINE through computerized database 
MEDLARS was mainly accessed through 
institutions, such as university libraries. In 1996, 
PubMed was launched but only as late as 1997 gave 
free access of MEDLINE to private home and 
office computers. PubMed Advanced Search 
Builder 
http://www.ncbi.nlm.nih.gov/pubmed/advanced 
uses keywords such as: Affiliation, All Fields, 
Author, Author First, Author Last, Journal, MeSH 
Major Topic, Title, Title/Abstract (Figure 1). It uses 
Booleans (AND, OR, NOT). You can query 
"(KMT2A[Title]) AND ((Acute myeloid leukemia) 
OR (Acute lymphoid leukemia))", you will get: 
Search results : Items 5. This only shows that the 
official name KMT2A remains totally ignored by 
scientists. If you replace KMT2A with MLL: 
"(MLL[Title]) AND ((Acute Myeloid Leukemia) 
OR (Acute lymphoid leukemia))", you get: Search 
results : Items 885. Which is what you were looking 
for. On the other hand, if you misuse the brackets in 
your query (e.g. "((KMT2A[Title]) AND Acute 
myeloid leukemia) OR Acute lymphoid leukemia", 
you will have a huge amount of background noise! 
Search results: Items 36,244. PubMed comprises of 
more than 25 million citations of biomedical 
literature from MEDLINE, life science journals, 
and online books. Citations may include links to 
full-text content from PubMed Central and 
publisher web sites. As a broader research engine, 
PubMed also runs in several other databases like 
MEDLINE and Index Medicus, providing older 
references of the print versions as well as some 
journals not yet cited, like Science.  
The research engine also accesses entries for an 
article before it gets indexed by the Medical Subject 
Headings (MeSH) and added to MEDLINE.  
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Figure 1:  PubMed Advanced Search Builder: choice of fields for a query. (http://www.ncbi.nlm.nih.gov/pubmed/advanced) 
 
Collections of full-text available books and other 
subsets of NLM records are available 
(https://www.nlm.nih.gov/pubs/factsheets/pubmed.
html). The references catalogued in PubMed often 
contain links to the full text articles, some of them 
are free of access and more often in PubMed 
Central (http://www.ncbi.nlm.nih.gov/pmc/) and 
local mirrors like UK PubMed Central 
(http://www.jisc-content.ac.uk/node/52) or Europe 
PMC (https://europepmc.org/). NLM catalogue 
contains all the necessary information about the 
journals that are indexed in PubMed 
(http://www.ncbi.nlm.nih.gov/nlmcatalog). PubMed 
records back to 1966, selectively to the year 1865, 
and very selectively to 1809; about 500,000 new 
records are added each year. As of this date, 
14,026,022 records are listed with their abstracts. 
Only journals achieving PubMed's scientific 
standards are indexed which, on the one hand, 
provides a way to control the quality of scientific 
publishing. PubMed, free of use, is an immense gift 
to the medical and scientific community. However, 
from the scientific editor's viewpoint, this quasi-
monopoly position has an adverse aspect: to be 
referenced by PubMed is a terrifying verdict, in 
terms of recognition. This is all the more 
concerning, as the Literature Selection Technical 
Review Committee's decisions have been known to 
create controversy among scientific editor's and 
publisher's communities. 
PubMed Central 
(http://www.ncbi.nlm.nih.gov/pmc/)  
PubMed Central (PMC) is a free archive of 
biomedical and life sciences journal literature at the 
U.S. National Institutes of Health's National Library 
of Medicine (NIH/NLM) developed by the National 
Center for Biotechnology Information (NCBI). 
PubMed Central should not be confused with 
PubMed. As an archive, PMC is designed to 
provide permanent access to all of its content. 
Articles are deposited by participating journals, as 
well as for author manuscripts that have been 
submitted in compliance with the public access 
policies of participating research funding agencies. 
Medline 
Medline is the U.S. National Library of Medicine 
(NLM) premier bibliographic database that contains 
more than 22 million references to journal articles 
in life sciences with emphasis on biomedicine. A 
distinctive feature of MEDLINE is that the records 
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are indexed with NLM Medical Subject Headings 
(MeSH). MEDLINE is the primary component of 
PubMed. 
Scopus (http://www.scopus.com/) 
Scopus is a large abstract and citation database of 
peer-reviewed literature: scientific journals (more 
than 60 million records in Scopus, which includes 
over 21,500 peer-reviewed journals), books (more 
than 113,000 books) and conference proceedings. It 
is owned by Elsevier and it is available online by 
subscription. 
II- Nomenclatures 
 Gene Nomenclature: HGNC 
(http://www.genenames.org/) 
The HUGO Gene Nomenclature Committee 
(HGNC) is the worldwide authority assigning 
standardised nomenclature to human genes. HGNC 
approves unique names and symbols for human 
loci, including protein coding genes, ncRNA genes 
and pseudogenes, gene families and associated 
resources including links to genomic, proteomic 
and phenotypic information, to allow more 
unambiguousity to scientific communication. This 
database contains 39,000 approved symbols (Gray 
KA et al., 2015). 
Nomenclature for the description of sequence 
variations (http://www.hgvs.org/mutnomen/) 
The nomenclature for the description of sequence 
variations is maintained by the Human Genome 
Variation Society (HGVS). When describing a 
variation, first, i) Indicates the reference sequence 
(e.g. coding DNA: "c."; RNA: "r."; Protein: "p."), 
followed by ii) the type of variation/mutation (e.g. 
base substitution: ">"; deletion: "del"). The 
following codes therefore, have the following 
meanings: "c.123A>G": on cDNA, A is replaced by 
G in 123; "p.P252R": on protein, at 252, proline (P) 
is replaced by arginine (R); "c.546delT": deletion of 
T in 546; "c.586591del": for six bases deleted, from 
586; "p.F508del": deletion of phenylalanine (F) in 
508. A summary is proposed at: 
http://atlasgeneticsoncology.org/Educ/NomMutID3
0067ES.html. 
International System for Human Cytogenetic 
Nomenclature (ISCN)  
ISCN is a language describing abnormal 
karyotypes. In logic and in mathematics languages 
with specific grammars have been invented with 
specific grammars (see 
https://en.wikipedia.org/wiki/Portal:Logic). The 
ISCN follows this model. It uses operands and, to 
act on them, unary and binary operators (e.g. "r" 
(ring) is an unary operator because it acts on one 
operand (one chromosome), and "t" (translocation) 
is a binary operator, because it acts on two 
operands, (the 2 chromosomes involved in the 
translocation). ISCN originates at the Denver 
conference, in 1960 (proposed nomenclature, 
1960). By periodic revisions and updates ISCN has 
now become ever more complicated (ISCN (2013). 
A new version will be released by the end of 2016: 
McGowan-Jordan J, Simons A and Schmid M. 
(eds) (2016) ISCN 2016 An International System 
for Cytogenomic Nomenclature. Reprint of 
Cytogenetic and Genome Research 149(1-2), but 
will not be freely accessible on the web. 
International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3) 
(http://www.who.int/classifications/icd/adaptations/
oncology/en/) 
For reasons of interoperability between different 
databases it is essential that a common language is 
found.  
The WHO/OMS has established the ICD-O code 
for International Classification of Diseases - 
Oncology, first published in 1976. The third edition 
of ICD-O (ICD-O3) contains an ICD-O3-TOPO, 
which provides a topographical identifier for 
different organs (e.g. C220: Liver; C339: Trachea), 
and an ICD-O3-MORPH, which provides basic and 
detailed description of pathology (e.g. respectively: 
801: Carcinoma, NOS (not otherwise specified); 
8013/3: Large cell neuroendocrine carcinoma; 922: 
Chondrosarcoma, NOS; 9221/3: Juxtacortical 
chondrosarcoma). A "/0" means: benign tumor 
(e.g.: 9220/0: Chondroma): "/1" means: borderline 
malignancy (e.g. 9751/1: Langerhans cell 
histiocytosis); "/2" means: malignant tumor in situ 
(e.g. 8500/2: Intraductal carcinoma, noninfiltrating, 
NOS); and "/3" means full malignancy. 
Nosology, thesaurus and census, with phylum of 
solid tumors and hematological malignancies can 
be found in the Atlas at: 
http://atlasgeneticsoncology.org/Tumors/Solid_Nos
ology.html and: 
http://atlasgeneticsoncology.org/Anomalies/ICD-
O_Hematology.html. This classification is not used 
by all databases (e.g. the Mitelman database and the 
COSMIC database use different classifications, 
with no apparent matching). This makes any 
integration of data by new resources complicated. 
III- Nucleic acid, genes and 
protein databases 
III-1 Nucleic acid databases 
The first database for DNA sequencing was The 
Los Alamos Sequence Database in 1979, which was 
consequently replaced by public GenBank 
((http://www.ncbi.nlm.nih.gov/genbank/) (Burks C 
et al., 1985) in 1982. The database was funded by 
the National Institutes of Health, the National 
Science Foundation, the Department of Energy, and 
the Department of Defense. Los Alamos National 
Laboratories (LANL) collaborated with several 
firms like Bolt, Beranek, and Newman to increase 
the size of the database. By the end of 1983 more 
than 2,000 sequences were stored in it.  
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Mid 1980s, the Intelligenetics bioinformatics 
company from Stanford University collaborated 
with LANL to manage the GenBank project (Burks 
C et al., 1991). Since it was one of the earliest 
bioinformatics community projects on the Internet, 
BIOSCI/Bionet news groups was created to 
promote open access communications among 
bioscientists. From 1989 to 1992, the GenBank 
project transitioned to the newly created National 
Center for Biotechnology Information (Benton D, 
1990).  
From 1982 to present day, the number of bases in 
GenBank has doubled roughly every 1,5 years 
(Benson DA et al., 2015). As of February 2016, 
GenBank version 212.0 contains 190,250,235 loci, 
207,018,196,067 bases, from 190,250,235 reported 
sequences 
(http://www.ncbi.nlm.nih.gov/genbank/statistics/). 
The GenBank database includes additional data sets 
that are constructed mechanically from the main 
sequence data collection, and therefore are excluded 
from this count. In parallel, the EMBL database 
was created in 1981 and since this date there is an 
International Nucleotide Sequence Database 
Collaboration (INSDC) which is a long-standing 
foundational initiative that operates between DDBJ, 
EMBL-EBI and NCBI. INSDC covers the spectrum 
of data raw reads, though alignments and 
assemblies to functional annotation, enriched with 
contextual information relating to samples and 
experimental configurations. In particular there are 
numerous evolutions with the development of 
massive sequencing with creation of more 
integrated structures as ENA (European Nucleotide 
Archive at EBI, http://www.ebi.ac.uk/services/dna-
rna) or SRA (Sequence read archive at NCBI, 
http://www.ncbi.nlm.nih.gov/sra/) (Cook CE et al., 
2016).  
In parallel with the genome projects, the need for 
the best representation of genomic and transcript 
sequences for diverse species has been the driver 
for creating consensus databases (as RefSeq, 
UCSC, Ensembl) with several methods of 
optimisation. 
III-2 Genes and Functions 
Genomic sequences and transcripts 
As mentioned in the general resources, several 
consensus nucleic sequence databases provide 
detailed structures of genes and isoforms. All the 
information can easily be visualized using different 
browsers (UCSC, Ensembl) or described in detail 
on the Entrez Gene (see above) page at NCBI. 
RefSeq (http://www.ncbi.nlm.nih.gov/refseq/) 
maintains and curates a database recording 
annotated genomic, transcript, and protein 
sequences. RefSeq release 71 provides sequences 
from over 55,000 organisms (more than 4,800  
viruses, 40,000 prokaryotes and 10,000 eukaryotes) 
(O'Leary NA et al., 2016). Ensembl 
(http://www.ensembl.org/) is a joint project 
between EMBL-EBI and the Wellcome Trust 
Sanger Institute to develop a software which 
develops and maintains automatic annotation of 
selected eukaryotic genomes (Gray KA et al., 
2015).  
The UCSC Genome Browser database is a large 
collection of 160 genome assemblies representing 
91 species (Rosenbloom KR et al., 2015) (Figures 2 
and 3: PAX5 at UCSC and at the Atlas site 
respectively). 
Some standardisation within CCDS and GenCode 
http://www.gencodegenes.org/ gives an up-to-date 
information on them.  
The nature of isoforms, expressed differently in 
normal tissues and in tumors, due to splicing 
variety, leads to protein product with different 
amino acid sequences.  
This reflects the variations in the structure in 
domains and in the 3D structure are the basis of the 
activity. On the other hand, the level of expression 
of transcript in different tissues can be obtained 
from SOURCE, GEO (Clough and Barett, 2016 ), 
Expression Atlas ( Petryszak et al., 2016), Gene 
expression viewer (Firebrowse), BioGPS 
(http://biogps.org/#goto=welcome) (Wu C et al., 
2016) (Figure 4). 
III-3 Protein sequence databases 
In parallel with the nucleic databases, the first 
protein database was established by M. Dayhoff as 
NBRF protein database in 1983, in continuity of the 
first comprehensive collection of macromolecular 
sequences in the Atlas of Protein Sequence and 
Structure, published from 1965-1978.  
This was followed by the development of 
SwissProt, a curated dataset, by Amos Bairoch in 
1986 (http://www.isb-sib.ch/sp30/the-history-of-
swiss-prot).  
With collaboration between the Swiss Institute of 
Bioinformatics and the EBI to lead in 2002 (in 
association with the PIR database) the SwissProt 
was extended to UniProt Knowledgebase 
(UniProtKB) in 1998, consisting in the curated 
UniProtKB/Swiss-Prot databank, its automatically 
annotated supplement TrEMBL, and the PIR 
protein database.  
Today, UniProtKB represents the world's most 
comprehensive catalogue of information on 
proteins. In the space of 30 years, the number of 
proteins entered in UniProtKB/Swiss-Prot has 
increased from 4,000 to 550,000 : 550,960 entries 
for the SwissProt part and 63,686,057 entries for 
the non-reviewed part for TrEMBL (Pundir S et al., 
2015). 
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Figure 2:  PAX5 gene with isoforms at UCSC (http://genome-euro.ucsc.edu/cgi-bin/hgGateway), Select Species: "Human"; 
Human Assembly: "Dec. 2013 (GRCh38/hg38)"; Position/Search Term: write "PAX5"; go!) 
 
 
 
Figure 3:  PAX5 gene and protein in the Atlas (http://atlasgeneticsoncology.org//Genes/PAX5ID62.html) 
 
 
General resources in Genetics and/or Oncology De Braekeleer E, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 294 
 
 
Figure 4: Expression of PAX3 in various tissues at BioGPS (http://biogps.org/#goto=genereport&id=5077) 
 
 
UniProt (http://www.uniprot.org/) 
The UniProt Knowledgebase (UniProt Consortium, 
2015) (UniProtKB, 
http://www.uniprot.org/uniprot/) is a hub for the 
collection of information on proteins with 
annotation. In addition to amino acid sequences, 
protein names and domain descriptions, taxonomic 
data and citation information, it also provides brief 
annotation information (Figure 5). UniProtKB 
consists of two sections: computationally analyzed 
"TrEMBL" and manually annotated "Swiss-Prot", 
with information extracted from curator-evaluated 
computational analysis and literature. UniProt is a 
collaboration between the European Bioinformatics 
Institute (EMBL-EBI, http://www.ebi.ac.uk/), the 
SIB Swiss Institute of Bioinformatics 
(http://www.isb-sib.ch/) and the Protein 
Information Resource (PIR, 
http://pir.georgetown.edu/.) 
It is comprised of two seperate tools: the Basic 
Local Alignment Search Tool (BLAST, 
http://www.uniprot.org/blast/), to find a region of 
local similarity between amino acids sequences 
used in identifying members of a gene family, and 
Align (http://www.uniprot.org/align/ ) to align two 
or more protein sequences. 
neXtProt (http://www.nextprot.org/db/)neXtProt 
(Gaudet P et al., 2015) is a resource for human 
proteins, including information on the exons, 
proteins sequences, function, subcellular 
localisation, expression, interactions and role in 
diseases (Figure 6). The major part of the 
information in neXtProt is obtained from the 
UniProt Swiss-Prot database but is gradually being 
complemented by original data. neXtProt contains 
20,055 protein entries, and is maintained by Amos 
Bairoch at the Swiss Institute of Bioinformatics and 
GeneBio. 
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Figure 5: PAX5 at UniProtKB (http://www.uniprot.org/uniprot/Q02548) 
 
 
 
 
Figure 6: PAX5 at neXtProt, tab "Function" (see on the left) (http://www.nextprot.org/db/entry/NX_Q02548) 
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Figure 7: PAX5 at PhosphoSitePlus (http://www.phosphosite.org/proteinAction.action?id=19058&showAllSites=true) 
 
 
PhosphoSitePlus 
(http://www.phosphosite.org/homeAction.action)  
PhosphoSitePlus (Hornbeck PV et al., 2015) is an 
excellent resource providing comprehensive 
information and tools for the study of protein post-
translational modifications (PTMs) including 
phosphorylation, ubiquitination, acetylation and 
methylation (Figure 7). PhosphoSitePlus contains 
curated data on 53,219 human, mouse and to a 
lesser extent rat proteins, with protein name, protein 
type, domain, cellular component, and molecular 
weight. It is an excellent website. PhosphoSitePlus 
is based at Cell Signaling Technology, Danvers, 
Massachusetts. 
PROSITE (http://prosite.expasy.org/) 
PROSITE (Sigrist CJ et al., 2013) is one of the 
oldest catalogs of protein signatures, consisting of 
documentation entries describing protein domains, 
families and functional sites, via a specific pattern 
of conserved residues (manually defined). 
PROSITE contains 1756 documentation entries. 
Pfam (http://pfam.xfam.org/) 
Pfam (Finn RD et al., 2016) is a collection of 
multiple sequence alignments and hidden Markov 
models covering many common protein domains. 
The identification of domains that occur within 
proteins can provide insights into their function. 
Pfam contains 16295 entries. InterPro and Pfam are 
based at EMBL-EBI.  
InterPro (http://www.ebi.ac.uk/interpro/) 
InterPro integrates PROSITE, Pfam and certain 
other resources in order to provide functional 
analysis of proteins by classifying them into 
families and predicting domains (with signatures) 
and important sites; InterProScan is the software 
package that allows sequences to be scanned 
against InterPro's signatures (Mitchell A et al., 
2015). 
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Figure 8: and 9: JAK2 and SQSTM1 at Atlas: protein domains (http://atlasgeneticsoncology.org//Genes/JAKID98.html and 
http://atlasgeneticsoncology.org//Genes/GC_SQSTM1.html) There are also data and iconography on pathways (Figure 10). 
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Figure 10: BCL6 regulation (involving PAX5) in the Atlas (http://atlasgeneticsoncology.org//Genes/BCL6ID20.html) 
 
Atlas of Genetics and Cytogenetics in Oncology 
and Haematology 
The Atlas presents highly curated paragraphs with 
the description of the protein listing domains and 
iconography, expression and localisation, function, 
homologs, and uniquely, a wide angle on cancers 
and other medical conditions where a gene or a 
protein is implicated (Figure 8 and 9). 
IV- Cards  
IV-1 Entrez Gene 
(http://www.ncbi.nlm.nih.gov/gen
e/) 
Entrez is NCBI's primary text search and retrieval 
system integrating the PubMed database of 
biomedical literature with 39 other literature and 
molecular databases including DNA and protein 
sequences, structures, genes, genomes, genetic 
variation and gene expression. Entrez Gene, 
dedicated to gene information, integrates data from 
a wide range of species. A record can include 
nomenclature, Reference Sequences (RefSeqs), 
maps, pathways, variations, phenotypes, and links 
to genome-, phenotype- and locus-specific 
resources worldwide. Entrez Gene catalogs 59,941 
human genes. Entrez Gene can be queried as a free 
text but also via a syntax with specific fields or 
filters (e.g. BRCA1[sym] ; 2[chr] AND adh*[sym] 
;..) with output in different formats. Once a result is 
obtained as a list of gene symbols, it is possible to 
link it to related data in another part of the Entrez 
database (e.g. list of publication in PubMed from a 
selected list of genes symbols) (NCBI Resource 
Coordinators, 2016).  
IV-2 Genecards 
(http://www.genecards.org/) 
Genecards is an integrative database that provides 
comprehensive, user-friendly information on all 
annotated and predicted human genes. It 
automatically integrates data from roughly 125 web 
sources and includes genomic, transcriptomic, 
proteomic, genetic, clinical and functional 
information.  
There are some affiliated databases as MalaCards 
"The human disease database" 
(http://www.malacards.org/) which is an integrated 
database of human diseases and their annotations, 
modeled on the architecture and richness of the 
GeneCards database of human genes (Fishilevich S 
et al., 2016).  
V- Genome cartography 
The cartography of genes on a genome has been the 
favoured mean to represent genomic information. 
With the human Genome Project, several types of 
viewers have been developed. To date, two sites are 
of first interest for human genetics: 
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V-1 UCSC 
(http://genome.ucsc.edu/) and 
UCSC-Cancer (https://genome-
cancer.ucsc.edu/.) 
The UCSC Genome Browser contains a reference 
sequence and working draft assemblies for a large 
collection of genomes. It also provides portals to 
ENCODE data at UCSC (2003 to 2012).  
The Genome Browser zooms and scrolls over 
chromosomes, presenting the work of annotators 
worldwide. The "Gene Sorter" shows expression, 
homology and other information on groups of genes 
that can be related in many ways (with a chosen set 
of tracks). "Blat" maps sequences to the genome 
quickly. The Table Browser provides convenient 
access to the underlying database. "VisiGene" lets 
you browse through a large collection of in situ 
mouse and frog images to examine gene expression 
patterns. "Genome Graphs" allows you to upload 
and display genome-wide data sets. The UCSC 
Genome Browser is developed and maintained by 
the Genome Bioinformatics Group, a cross-
departmental team within the UC Santa Cruz 
Genomics Institute at the University of California 
Santa Cruz (UCSC).  
A parallel browser has been developed for 
visualizing and analysing cancer data. The UCSC 
Cancer Browser https://genome-
cancer.ucsc.edu/proj/site/help/) allows researchers 
to explore cancer genomics data and its associated 
clinical information in an interactive manner. Data 
can be viewed in several different ways, including 
by value, chromosome location, clinical features, 
biological pathways or genes of interest. It is also 
possible to quickly perform and easily view 
statistical analysis on subsets of the data. The data 
heatmap displays genome-wide data from copy 
number, transcriptome, protein, epigenetic, 
mutation, sh/siRNA, and PARADIGM pathway 
analysis studies as well as associated clinical 
information. The left column shows datasets that 
are currently in view along with a button to add 
more. Today the system has 720 datasets for an 
exploration (Goldman M et al., 2015).  
V-2 Ensembl 
(http://www.ensembl.org)  
Ensembl produces genomic datasets through a 
system that is designed to analyse, store and 
distribute data, and which enables interpretation 
through open data release. As a hub of reference 
and baseline data similar to UCSC Genome 
Browser and RefSeq, Ensembl also distributes 
created datasets and promotes standards and 
interoperability between genomic resources. In 
addition, Ensembl collaborates with and often plays 
active leadership roles in projects such as 
ENCODE, the "Genome Reference Consortium" 
(GRC), the "Global Alliance for Genomics and 
Health" (GA4GH) and GENCODE. Ensembl is 
updated 4-5 times annually with each release 
representing a data and software freeze. Ensembl 
provides two sets of human data based on the hg19 
genome build 
(http://grch37.ensembl.org/Homosapiens/Info/Index
) which has been updated by the data set based on 
the December 2013 Homo sapiens high coverage 
assembly GRCh38 from the Genome Reference 
Consortium. This assembly is used by UCSC to 
create their hg38 database. The data set consists of 
gene models built from the alignments (for 
comparison) of the human proteome as well as from 
alignments of human cDNAs. This release of the 
assembly has the following properties: assembly 
length with a total of 3.4 Gb, chromosome length 
total 3.1 Gb (excluding haplotypes). It also includes 
261 alternate loci scaffolds, mainly in the LRC/KIR 
complex on chromosome 19 (35 alternate sequence 
representations) and the MHC region on 
chromosome 6 (7 alternate sequence 
representations) (Yates A et al., 2016).  
VI- Structural variation databases 
Since the mid 2000's, there were several studies of 
copy number variation of DNA sequences to 
construct CNV map of the human genome through 
different populations using SNP genotypes and 
CGH (Iafrate AJ et al., 2004; Redon R et al., 2006). 
It is becoming clear that genomic structural 
variation (variation ranging from tens to millions of 
base pairs in size, and including insertions, 
deletions, inversions, translocations and locus copy 
number changes) accounts for individual 
differences at the DNA sequence level in humans 
and can play a major role in diseases. Many 
databases have integrated data produced in the 
literature.  
VI-1 dbVar 
(http://www.ncbi.nlm.nih.gov/dbv
ar/) 
dbVar is the NCBI's database of genomic structural 
variation. It contains data of insertions, deletions, 
duplications, inversions, multi-nucleotide 
substitutions, mobile element insertions, 
translocations, and complex chromosomal 
rearrangements (NCBI Resource Coordinators, 
2016).  
VI-2 DGV - Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home)  
DGV is a database with an objective to provide a 
comprehensive summary of structural variation in 
the human genome. Structural variation is defined 
as genomic alterations that involve segments of 
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DNA that are larger than 1kb. It also annotates 
InDels in 100bp-1kb range. The content of the 
database is only representing structural variations 
identified in healthy control samples (MacDonald 
JR et al., 2014).  
VI-3 DECIPHER 
(https://decipher.sanger.ac.uk/) 
DECIPHER (DatabasE of Genomic variants and 
Phenotype in Humans using Ensembl Resources) is 
an interactive web-based database which 
incorporates a series of tools designed to aid the 
interpretation of genomic variants. DECIPHER 
enhances clinical diagnosis by retrieving 
information from a variety of bioinformatics 
resources relevant to the variant found in a patient. 
The patient's variant is displayed in the context of 
both normal variation and pathogenic variation 
reported at that locus, thereby facilitating 
interpretation (Firth HV et al., 2009).  
VI-4 1000 Genomes 
(http://www.1000genomes.org/) 
The 1000 Genomes Project beneficiated from the 
progress in sequencing technology, which sharply 
reduced the cost of sequencing. It was the first 
project to sequence the genomes of a large number 
of people, to provide a comprehensive resource on 
human genetic variation. Data from the 1000 
Genomes Project was quickly made available to the 
worldwide scientific community through freely 
accessible public databases.  
In continuation of the 1000 Genome project 
(sequencing 1000 human genome as exomes or 
whole genomes), the International Genome Sample 
Resource (IGSR) aims to expand information to 
new populations, a better coverage for presenting a 
uniform analysis set. Data corresponds to both 
single nucleotide and structural variants (1000 
Genomes Project Consortium et al., 2015).  
The 1000 Genomes Project operated between 2008 
and 2015, creating the largest public catalogue of 
human variation and genotype data. As the project 
ended, the Data Coordination Centre at EMBL-EBI 
received continuous funding from the Wellcome 
Trust to maintain and expand the resource. The 
International Genome Sample Resource (IGSR) is 
maintaining and extending the 1000 Genomes 
Project data.  
VII- Polymorphism databases 
It is important to distinguish between 
polymorphisms due to a change in a single 
nucleotide (SNP) as the variability within a 
population and mutations acquired in a neoplastic 
process. The determination of variants was 
previously obtained by SNP arrays, but is nowadays 
performed by massive parallel sequencing. As a 
result, a huge quantity of polymorphisms and 
mutations in tumors are compared to controls. The 
landscape of the majority of recurrent mutations is 
now known and can be used for diagnosis.  
VII-1 dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP
/overview.html)  
dbSNP is the main repository of Single Nucleotide 
Polymorphisms: A key aspect of research in 
genetics is associating sequence variations with 
heritable phenotypes. The most common variations 
are single nucleotide polymorphisms (SNPs), which 
occur approximately once every 100 to 300 bases. 
Because SNPs are expected to facilitate large-scale 
association genetics studies, there has recently been 
great interest in SNP discovery and detection. The 
database contains 164,986,514 SNPs for several 
species (NCBI Resource Coordinators, 2016).  
VII- 2 HAPMAP 
(http://hapmap.ncbi.nlm.nih.gov/i
ndex.html.en)  
The International HapMap Project was a 
collaboration of scientists and funding agencies 
from Canada, China, Japan, Nigeria, the United 
Kingdom and the United States who wanted to 
develop a public resource that helps researchers 
find genes associated with human disease and 
consequently give response to pharmaceuticals. The 
goal of the project was to compare genetic 
sequences of different individuals in order to 
identify chromosomal regions where genetic 
variants are shared. An interface 
(http://hapmap.ncbi.nlm.nih.gov/cgi-
perl/gbrowse/hapmap28B36/) permits to query all 
the data collected in phases 1, 2 and 3 of the project 
(International HapMap 3 Consortium et al., 2010).  
VII-3 1000 Genomes Project (see 
above)  
As the Phase3, 1000 Genomes variants are in the 
process of being archived at dbSNP and DGVa and 
a version of the Ensembl databases has been 
created, containing the phase3 autosomal variants. 
This is presented alongside the v80 GRCh37 
Ensembl core and regulatory databases. This release 
represents more than 80M short variants with 
genotypes for 2,504 individuals across 26 
populations. The latest major update was realeased 
to the 1000 Genomes Website in February 2016 
(1000 Genomes Project Consortium et al., 2015).  
VII- 4 Exome Variant server (EVS) 
(http://evs.gs.washington.edu/EV
S/) 
The goal of the NHLBI GO Exome Sequencing 
Project (ESP) is to discover novel genes and 
mechanisms contributing to heart, lung, and blood 
General resources in Genetics and/or Oncology De Braekeleer E, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 301 
 
disorders by pioneering the application of next-
generation sequencing of the protein coding regions 
of the human genome across diverse, richly-
phenotyped populations and to share these datasets 
and findings with the scientific community to 
extend and enrich the diagnosis, management and 
treatment of the aforementioned disorders. Two 
categories of populations are considered: European-
American and African-American. Some criteria or 
impact scores of the variation on the gene function 
are also presented (Tennessen JA et al., 2012).  
VIII- Portals/Working consortium 
VIII-1 TCGA 
(http://cancergenome.nih.gov/) 
Since 2005 TCGA (The Cancer Genome Atlas) has 
indexed genetic mutations responsible for cancer, 
using genome sequencing and bioinformatics. 
TCGA applies high-throughput genome analysis to 
progress our ability to diagnose, treat, and prevent 
cancer.  
TCGA is administered by the National Cancer 
Institute's Center for Cancer Genomics and the 
National Human Genome Research Institute funded 
by the US government. A pilot project, initiated in 
2006, focused on analysing three types of human 
cancers: Glioblastoma multiforme, lung cancer, and 
Ovarian cancer (Cancer Genome Atlas Research 
Network, 2011).  
In 2009, a second phase started, 20-25 different 
tumor types were included to complete the genomic 
characterization and sequence analysis (Figure 11). 
TCGA surpassed that goal, characterizing 33 
different cancer types including 10 rare cancers 
(http://cancergenome.nih.gov/abouttcga/overview). 
Funding is split between genome characterization 
centers (GCCs), which perform the sequencing, and 
genome data analysis centers (GDACs), which 
perform the bioinformatic analyses. 
The project scheduled 500 patient samples using 
several analysing techniques: Gene expression 
profiling, copy number variation profiling, SNP 
genotyping, genome wide DNA methylation 
profiling, microRNA profiling, and exon 
sequencing of 1,200 or more genes (Figure 12). 
TCGA is sequencing some tumors, including at 
least 6,000 candidate genes and microRNA 
sequences.  
This targeted sequencing is being performed by all 
three sequencing centers using hybrid-capture 
technology. In phase II, TCGA is performing whole 
exon sequencing on 80% of the cases and whole 
genome sequencing on 80% of the cases used in the 
project. 
 
Figure 11: Acute Myeloïd Leukemia query in TCGA datasets with the Data Matrix option (https://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm?mode=ApplyFilter) 
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Figure 12: PAX8 gene fusions in TCGA (http://54.84.12.177/PanCanFusV2/) 
 
 
VIII-2 ICGC (https://icgc.org/) 
ICGC (The International Cancer Genome 
Consortium) was organized to launch and 
coordinate a large number of research projects with 
the common aim of comprehensively elucidating 
the genomic changes present in many forms of 
cancers.  
Funding and Research members proposing a project 
must agree to the ICGC's policies (Figure 13). 
ICGC's primary objectives are to generate 
comprehensive catalogues of genomic 
abnormalities (somatic mutations, abnormal 
expression of genes, epigenetic modifications) in 
tumors representing 50 different cancer types 
and/or subtypes which are of clinical and societal 
importance across the globe and make the data 
available to the entire research community.  
Each of the 50 projects will generate the genomic 
analyses on approximately 500 cancer samples of 
each class.  
This will cover the various types and subtypes but 
cannot exhaustively cover the full spectrum of 
cancer types. The ICGC facilitates communication 
among the  
members and provides a forum for coordination 
with the objective of maximizing efficiency among 
the scientists working to understand, treat, and 
prevent these diseases.  
ICGC data release 20 (November 2015) comprises 
data from 14,767 cancer genomes in total.  
The ICGC Data Portal (https://dcc.icgc.org/) is 
developed by the Ontario Institute for Cancer 
research (OICR) (Zhang J et al., 2011). 
VIII-3 OASIS (http://www.oasis-genomics.org/) 
OASIS, which was created by Pfizer Oncology 
Research Computational Biology in collaboration 
with Research Business Technology (RBT), is an 
open-access web portal that provides the possibility 
to run exploratory and integrative analyses of 
somatic mutations, copy number variation (CNV) 
and gene expression data (Figure14).  
This data originates from thousands of different 
tissues of tumour samples, normal tissues and cell 
lines thus representing a broad spectrum of 
malignancies. This portal contains 30 datasets, 
mainly from TCGA, with access to mutations, copy 
number variation, expression (microarrays) and 
expression (RNA-Seq). 
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Figure 13: ICGC International Cancer Genome consortium: Home page (https://icgc.org/) 
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Figure 14: OASIS portal Home page (http://www.oasis-genomics.org/) 
 
VIII-4 Firebrowse 
(http://firebrowse.org/) 
This portal developed at the Broad Institute 
presents 38 cancer cohorts and 14,729 samples, 
mainly from the TCGA program, and provides an 
option to browse reports, clinical analysis, copy 
number variation, mutation, expression, and to 
download data for further analysis (Figure 15) See 
the tutorial for a complete view of possibilities 
(http://firebrowse.org/tutorial/FireBrowse-
Tutorial.pdf). 
VIII-5 GDC 
(https://gdc.nci.nih.gov/)  
The NCI's Genomic Data Commons (GDC) 
provides the cancer research community with a 
unified data repository that enables data sharing 
across cancer genomic studies in support of 
precision medicine. (note added in proof, June 6, 
2016). The GDC supports several cancer genome 
programs at the NCI Center for Cancer Genomics 
(CCG), including The Cancer Genome Atlas 
(TCGA), Therapeutically Applicable Research to 
Generate Effective Treatments (TARGET), and the 
Cancer Genome Characterization Initiative (CGCI). 
The GDC Data Portal provides a platform for 
efficiently querying and downloading high quality 
and complete data. The GDC also provides a GDC 
Data Transfer Tool and a GDC API for 
programmatic access.  
IX- Impact on diseases 
IX-1 OMIM 
"Mendelian Inheritance in Man: Catalogs of 
Autosomal Dominant, Autosomal Recessive and X-
linked Phenotypes" was first published in 1966 by 
Victor A. McKusick (Johns Hopkins University 
Press), after a catalog of X-linked traits, published 
in 1962. In parallel, the "Human Gene Mapping" 
was first organized in New Haven in 1973, and 
mapped 119 and 100 loci respectively to confirmed 
or provisional/tentative chromosome assignements 
(Birth Defect, 1974).  
The first edition of the "Mendelian Inheritance in 
Man: Catalogs of Autosomal Dominant, Autosomal 
Recessive and X-linked Phenotypes" had 1487 
entries and no mapped autosomal loci. Victor A. 
McKusick published 12 editions, the last one in 
1998, of his catalog. "Online Mendelian Inheritance 
in Man" (OMIM, http://omim.org/) was 
consequently published online. OMIM is a 
continuously updated catalog of human genes and 
genetic disorders and traits, with particular focus on 
the molecular relationship between genetic 
variation and phenotypic expression (Amberger JS 
et al., 2015).  
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Figure 15: PAX5 expression at FireBrowse (http://firebrowse.org/viewGene.html?gene=PAX5). 
 
As of April 2016, it consists of 23,460 entries: 
15,237 gene descriptions, 4,705 phenotypes with 
known molecular basis, an additional 1,626 
phenotypes with unknown molecular basis, and 
1892 other entries. Gene entries start at: * 100640. 
Aldehyde dehydrogenase 1 family, member A1; 
ALDH1A1 Cytogenetic location: 9q21.13, 
Genomic coordinates (GRCh38): 9:72,900,661-
72,953,316, and ends with * 616906. Cancer 
susceptibility candidate 1; CASC1. Phenotypes 
with known molecular basis entries start at: # 
100100. Prune belly syndrome; PBS, Cytogenetic 
location: 1q43, and ends with # 616903. Nucleoside 
diphosphate-linked moiety X motif 15 deficiency; 
NUDT15D. OMIM describes somatic mutations in 
genes (11,139 entries for the term "mutation"). It is 
a very well curated database, with excellent 
reliability. Unfortunately the addition process of 
data as literature is published, by successive 
layerings/sedimentation makes it sometimes a 
laborious consultation. OMIM is authored and 
edited at the McKusick-Nathans Institute of Genetic 
Medicine, Johns Hopkins University School of 
Medicine.  
IX-2 ClinVar 
(http://www.ncbi.nlm.nih.gov/clin
var/intro/) 
ClinVar is designed to provide a public archive of 
reports of the relationships among human variations 
and phenotypes, with supporting evidence. By 
doing so, ClinVar facilitates access to and 
communication about the relationships asserted 
between human variation and observed health 
status, and the history of that interpretation. 
ClinVar collects reports of variants found in patient 
samples, and assertions made regarding their 
clinical significance. The alleles described in 
submissions are mapped to reference sequences, 
and reported according to the HGVS standard. 
ClinVar then presents the data for interactive users 
in daily workflow and other local applications. 
ClinVar works in collaboration with interested 
organizations to meet the needs of the medical 
genetics community as efficiently and effectively as 
possible (Harrison SM et al., 2016).  
IX-3 MedGen 
(http://www.ncbi.nlm.nih.gov/med
gen/) 
MedGen is an NCBI portal of information about 
human disorders and other phenotypes having a 
genetic component. MedGen is structured to serve 
health care professionals, medical genetics 
community and other interested parties by 
providing centralized access to diverse content. 
MedGen aggregates the plethora of terms used for 
particular disorders into a specific concept, 
providing a "Rosetta stone" for stakeholders who 
may use different names for the same disorder. 
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Maintaining a clearly defined set of concepts and 
terms for phenotypes is essential in supporting 
characterization of genetic variation by its specific 
phenotypes effect. The assignment of identifiers for 
those concepts allows computational access to 
phenotypic information, an essential requirement 
for the large-scale analysis of genomic data. (NCBI 
Resource Coordinators, 2016).  
IX-4 dbGaP 
(http://www.ncbi.nlm.nih.gov/dbg
ap/) 
The database of Genotypes and Phenotypes 
(dbGaP) was developed to archive and distribute 
the data and results from studies where the 
interaction of genotype and phenotype in Humans 
has been investigated.  
IX-5 SNPs3D 
(http://www.snps3d.org/) 
SNPs3D is a website which assigns molecular 
functional effects of non-synonymous SNPs based 
on structure and sequence analysis. The site 
presents a data mining method to infer candidate 
SNP for 16 types of cancer (e.g. more than 1,000 
genes potentially implicated in breast cancer: 
http://www.snps3d.org/modules.php?name=Candid
ate&disease=BREAST%20CANCER) (Yue P and 
Moult J, 2006).  
IX-6 GTR 
(http://www.ncbi.nlm.nih.gov/gtr/) 
The Genetic Testing Registry (GTR) provides a 
central location for voluntary submission of genetic 
test information by providers. The scope includes 
purpose of the test, methodology, validity, evidence 
of its usefulness and laboratory contacts and 
credentials. The overarching goal of the GTR is to 
advance public health research to include the 
genetic basis of health and disease (Rubinstein WS 
et al., 2013).  
IX-7 ClinGen 
(https://www.clinicalgenome.org/)  
ClinGen is a National Institutes of Health (NIH)-
funded resource dedicated to building an 
authoritative central resource that defines the 
clinical relevance of genes and variants for use in 
precision medicine and research. This resource has 
several goals for building a genomic knowledge 
base to improve patients care.  
X- Pathology 
X-1 Authoritative books in 
pathology are the following:  
The "Rosai and Ackerman's Surgical Pathology" 
was first published in 1953. The tenth edition was 
published in 2011 by Elsevier, and contains 2892 
pages. It includes clinical features, morphologic, 
immunohistochemical and molecular genetic 
features and prognosis, with a very large 
iconography. "WHO/IARC Classification of 
Tumours series" (http://publications.iarc.fr/Book-
And-Report-Series/Who-Iarc-Classification-Of-
Tumours) is not on free access, except editions 
prior to 2006, which are on free access in pdf 
format. The Armed Forces Institute of Pathology 
(AFIP) publishes series of the "AFIP Atlas of 
Tumor Pathology".  
The WHO/OMS code, the ICD-O3, is not used by 
all databases (e.g. the Mitelman database or the 
COSMIC database have their own classification 
system, with no apparent matching). This is an 
obstacle for the integration of data by new 
resources.  
X-2 Atlas of Genetics and 
Cytogenetics in Oncology and 
Haematology 
The Atlas provides complete description of 
diseases, with papers similar to those found in the 
"Rosai and Ackerman's Surgical Pathology" or the 
"WHO/IARC Classification of Tumours series" 
(see above) with following restrictions: on the one 
hand, many tumor types are still missing from the 
Atlas; on the other hand, articles on genes closely 
related to these diseases are found, right next, in the 
Atlas, but not in the Rosai nor in the WHO's books, 
since this is out of their purpose. 
X-3 PathologyOutlines 
(http://pathologyoutlines.com/) 
PathologyOutlines provides information to 
practicing pathologists, with gross and microscopic 
images and summaries on CD markers and 
immunohistochemical stains and molecular 
markers.  
X-4 The United States and 
Canadian Academy of Pathology 
(USCAP, http://www.uscap.org/) 
USCAP is a provider of continuing medical 
education (CME) for pathologists to improve their 
practices. The Virtual Slide Box 
(http://uscapknowledgehub.org/index.htm?vsbindex
.htm) and Juan Rosai's collection 
(http://rosaicollection.org/) are collections of 
several hundred slides with case reports and 
diagnoses.  
XI- Cancer Registries 
Cancer registries are organizations seeking to 
collect, store, analyze, and report data on various 
cancers for epidemiological purposes, for providing 
statistics on the occurrence of cancer in a defined 
population, and for obtaining a framework to assess 
the impact of cancer in a given population. Cancer 
registries are crucial for healthcare policy planning. 
They are key data source for clinical research, 
(epidemiology, study of carcinogens, evaluation of 
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treatments), providing the assessment of the care 
structures and care pathways, and research tools for 
social sciences and humanities (see 
https://www.iarc.fr/en/publications/pdfs-
online/epi/cancerepi/CancerEpi-17.pdf)  
XI-1 International Agency for 
Research on Cancer (IARC, 
http://www.iarc.fr/) 
The IARC is the outcome of an initiative by a group 
of leading French public figures; it was created on 
20 May 1965, by a resolution of the World Health 
Assembly (http://www.iarc.fr/en/about/iarc-
history.php). IARC is the specialized cancer agency 
of the World Health Organization (WHO/OMS). 
The objective of the IARC is to promote 
international collaboration in cancer research. The 
Agency is inter-disciplinary. Emphasis is placed on 
elucidating the role of environmental and lifestyle 
risk factors and studying their interplay with 
genetic background. IARC publishes the "Cancer 
Incidence in Five Continents" series and 
GLOBOCAN (Figure 16). The aim of the 
GLOBOCAN project 
(http://globocan.iarc.fr/Default.aspx) is to provide 
contemporary estimates of the incidences of, 
mortality and prevalence of major types of cancer, 
at national level, for 184 countries of the world. 
XI-2 International Association of 
Cancer Registries (IACR, 
http://www.iacr.com.fr/). The IACR 
(not to be confused with the IARC) was founded in 
1966 as a professional society dedicated to 
fostering the aims and activities of cancer registries. 
It is a non-governmental organization which has 
held official relation with the World Health 
Organization since January 1979. With IACR 
IARC has developed with CanReg5, an open source 
tool to input, store, check and analyze cancer 
registry data. IACR has developed classifications 
(the successive editions of the International 
Classification of Diseases for Oncology, published 
by WHO), guidelines for registry practices and 
standard definitions. quality control, consistency 
checks and basic analysis of data, making data 
comparable between registries.  
XI-3 Examples: The European 
Network of Cancer Registries 
(ENCR, http://www.encr.eu/) has the 
same role in Europe as IACR has worldwide. The 
National Program of Cancer Registries (NPC, 
http://www.cdc.gov/cancer/), maintained by the 
Centers for disease control and prevention (CDC), 
collects data on cancer occurrence (including the 
type, extent, and location of the cancer), the type of 
initial treatment, and outcomes in the USA. The 
Surveillance, Epidemiology, and End Results 
(SEER, http://seer.cancer.gov/) program of the 
National Cancer Institute provides information on 
cancer. Research is supported by grants from the 
SEER. Quality improvement is another part of the 
SEER activities and it is dedicated to improving 
data quality by performing rigorous quality control 
studies and various data assessments. Union for 
International Cancer Control (UICC, 
http://www.uicc.org/). Founded in 1933, UICC 
brings together 900 organisations (cancer societies, 
ministries of health, research institutes and patient 
groups) over across 155 countries.  
XII- Patient associations and 
interfaces between science and 
patients - freely accessible 
services 
XII-1 Associations of parents and 
friends of patients 
These associations of parents of patients with a rare 
disease are precious. They give moral support and 
help, and offer practical guidances and information 
about social benefits, subsidies and day-to-day life 
to families affected by illness. They often establish 
a program of grants for research (e.g. Xeroderma 
Pigmentosum Society (http://www.xps.org/, 
Sarcoma Foundation of America 
(http://www.curesarcoma.org/), Union for 
International Cancer Control (UICC) 
(http://www.uicc.org/)).  
XII-2 interfaces between science 
and patients 
GeneTests (https://www.genetests.org)  
GeneTests (Pagon RA, 2006) provides information 
for 4,552 disorders 
(https://www.genetests.org/disorders/), 5,385 genes 
(https://www.genetests.org/genes/) (e.g. RUNX1 
RUNX1 and contacts with/for: 79,009 laboratory 
tests (https://www.genetests.org/tests/), 680 
laboratories 
(https://www.genetests.org/laboratories/) and 1,067 
clinics (https://www.genetests.org/clinics/).  
NORD (http://rarediseases.org)  
NORD provides information on more than 1,300 
rare diseases (e.g. Carcinoid syndrome 
http://rarediseases.org/rare-diseases/carcinoid-
syndrome/), state health insurance information, 
guides for physicians, and patient assistance 
programs. They also provide grants to academic 
scientists for translational or clinical studies to help 
patients obtain life-saving or life-sustaining 
medication they could not otherwise afford.  
Orphanet (http://www.orpha.net/) 
Orphanet (Rath et al., 2012) offers an inventory of 
rare diseases with data on 5,833 diseases (e.g. 
Fanconi anaemia), an inventory of orphan drugs, 
list of 6,636 expert centres and 3,280 laboratories, 
General resources in Genetics and/or Oncology De Braekeleer E, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 308 
 
19,894 professionals for genetic counselling and 
medical management. Orphanet does not provide 
gene annotations. They hold a large partnership  
from 38 countries participating in the Orphanet 
consortium. They maintain large disease registries 
in Europe. 
 
 
Figure 16: Surveillance system for cancers: GLOBOCAN 2012. Top: Incidence; Bottom: Mortality. 
((http://globocan.iarc.fr/Default.aspx) 
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